Open Clinical Trial, uncontrolled, dose escalation, the application of IGBC-300 in microinvasive cancer, carcinoma in situ and severe dysplasia of the cervix.

Trial Profile

Open Clinical Trial, uncontrolled, dose escalation, the application of IGBC-300 in microinvasive cancer, carcinoma in situ and severe dysplasia of the cervix.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs CIGB 300 (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions
  • Acronyms CERVISEG-300-I
  • Most Recent Events

    • 20 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record
    • 14 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top